Compound from the avermectin family for treating and/or preventing folliculitis
View Patent ↗A compound from the avermectin family is described for use in treating and/or preventing folliculitis caused by anti-cancer agents and more particularly by agents for targeted therapy.
1. A method of treating folliculitis caused by an anti-cancer agent, the method comprising administering an effective amount of a compound of the avermectin family to an individual subject in need thereof, wherein the folliculitis exhibits proliferation of Staphylococcus aureus.
2. The method as claimed in claim 1 , wherein the anti-cancer agent is a chemotherapy agent or a targeted-therapy agent.
3. The method as claimed in claim 2 , wherein the targeted-therapy agent is selected from the group consisting of agents which have an anti-EGFR activity and MEK-inhibiting agents.
4. The method as claimed claim 1 , wherein the compound of the avermectin family is selected from the group consisting of ivermectin, avermectin, abamectin, doramectin, eprinomectin, selamectin, aversectin B, AB or C, emamectin B1b or latidectin.
5. The method as claimed in claim 1 , wherein the compound of the avermectin family is ivermectin.
6. The method as claimed in claim 3 , wherein the therapeutic agent having an anti-EGFR activity is selected from the group consisting of cetuximab, gefitinib, erlotinib, panitumumab lapatinib, and mixtures thereof.
7. The method as claimed in claim 3 , wherein the MEK-inhibiting targeted-therapy agent is selected from the group consisting of trametinib, selumetinib, binimetinib and cobimetinib.
8. The method as claimed in claim 1 , wherein the compound is a pharmaceutical composition.
9. The method as claimed in claim 8 , wherein the composition is in a form suitable for topical administration.
10. The method as claimed in claim 9 , wherein the composition is in the form of an emulsion, cream, lotion, gel, solution or salve.
11. The method as claimed in claim 1 , wherein the composition comprises from 0.001% to 10% by weight of the compound of the avermectin family, relative to the total weight of the composition.
12. The method as claimed in claim 1 , wherein the composition comprises 1% by weight of the compound of the avermectin family in comparison with the total weight of the composition.
13. The method as claimed in claim 11 , wherein the composition comprises from 0.001% to 8% by weight of compound of the avermectin family.
14. The method as claimed in claim 11 , wherein the composition comprises from 0.001% to 5% by weight of compound of the avermectin family.
15. The method as claimed in claim 11 , wherein the composition comprises from 0.1% to 3% by weight of compound of the avermectin family.